{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:57:04Z","timestamp":1781114224840,"version":"3.54.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anemia is a common and multifactorial complication following kidney transplantation, significantly impacting patient morbidity and graft survival. Parvovirus B19 (B19V), a DNA virus targeting erythroid progenitor cells, is an increasingly recognized cause of refractory anemia in kidney transplant recipients (KTRs), but data from Indian populations remain sparse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center case series evaluated 10 KTRs diagnosed with B19V infection at the Institute of Nephro Urology, Bengaluru, from January 2021 to February 2025. Inclusion criteria encompassed KTRs with persistent anemia unresponsive to routine correction, confirmed by positive polymerase chain reaction (PCR) for B19V and\/or characteristic bone marrow findings. Clinical parameters, laboratory data, immunosuppression details, treatment, and outcomes were collected prospectively over a minimum 3-months follow-up. Treatment included reduction of immunosuppression, with adjunct intravenous immunoglobulin (IVIg) for non-responders, and use of erythropoiesis-stimulating agent Desidustat as adjunct treatment in all cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 117 transplant recipients, 8.5% developed B19V infection, with a median infection onset of 6 weeks (range 2\u2013462 weeks). All (100%) presented with fatigue and hypoproliferative anemia (reticulocyte count &amp;lt; 1%). 30% patients also had leukopenia and thrombocytopenia. 60% patients required IVIg post-reduction of immunosupression, achieving hematologic recovery within 4 weeks. Eight patients needed packed red blood cell transfusions (range 1\u20138 units). Two patients succumbed to severe infections unrelated to B19V. Statistical analysis confirmed significant decline in hemoglobin (mean reduction 3.72 \u00b11.22 g\/dL,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Parvovirus B19 is an important yet treatable cause of refractory anemia in KTRs. Early diagnosis by PCR and tailored management incorporating reduction in immunosuppression and IVIg can result in favorable outcomes. Routine surveillance is not warranted, but targeted testing should be considered in refractory anemia cases, particularly in resource-limited settings. Further studies are needed to optimize therapeutic strategies and validate novel treatments such as Desidustat.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1686727","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:41Z","timestamp":1765521281000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Silent saboteur: parvovirus B19 (B19V) and its impact on refractory post-transplant anemia"],"prefix":"10.3389","volume":"12","author":[{"given":"Mythri","family":"Shankar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varalaxmi","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwarak Sampath","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhara","family":"C. G.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e7906","DOI":"10.1002\/ccr3.7906","article-title":"Relapsing anemia associated with parvovirus B19 infection in a kidney transplant recipient: a case report and review of the literature.","volume":"11","author":"Yaghoubi","year":"2023","journal-title":"Clin Case Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"511","DOI":"10.25259\/IJN_127_2024","article-title":"Parvovirus B19 infection as a cause of refractory anemia in kidney transplant recipients: a case series.","volume":"35","author":"Hegde","year":"2025","journal-title":"Indian J Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1016\/S1473-3099(24)00560-7","article-title":"Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literature.","volume":"25","author":"Berti","year":"2025","journal-title":"Lancet Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4103\/UA.UA_89_19","article-title":"Epidemiology of parvovirus B19 and anemia among kidney transplant recipients: a meta-analysis.","volume":"12","author":"Thongprayoon","year":"2020","journal-title":"Urol Ann."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e241156","DOI":"10.7326\/aimcc.2024.1156","article-title":"Parvovirus B19 infection in kidney transplant recipients.","volume":"4","author":"Hatem","year":"2025","journal-title":"AIM Clinical Cases."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101667","DOI":"10.1016\/j.trim.2022.101667","article-title":"Parvovirus B19 infection in kidney transplant recipients: a prospective study in a teaching hospital in Shanghai.","volume":"74","author":"Huang","year":"2022","journal-title":"China. Transpl Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"ofad079","DOI":"10.1093\/ofid\/ofad079","article-title":"Transient parvovirus B19 DNAemia after kidney transplantation: a 2-sided story.","volume":"10","author":"Russcher","year":"2023","journal-title":"Open Forum Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fcimb.2018.00166","article-title":"Recent advances in replication and infection of human parvovirus B19.","volume":"8","author":"Ganaie","year":"2018","journal-title":"Front Cell Infect Microbiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.mjafi.2023.08.005","article-title":"Parvovirus B19 infection after kidney transplantation: a single centre experience.","volume":"79","author":"Singh","year":"2023","journal-title":"Med J Armed Forces India."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105020","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.","volume":"159","author":"Zheng","year":"2020","journal-title":"Pharmacol Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jviromet.2015.03.006","article-title":"new quantitative PCR for human parvovirus B19 genotypes.","volume":"218","author":"Toppinen","year":"2015","journal-title":"J Virol Methods."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S0272-6386(99)70021-1","article-title":"Parvovirus B19 infection causing red cell aplasia in renal transplantation on tacrolimus.","volume":"34","author":"Wong","year":"1999","journal-title":"Am J Kidney Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1016\/s0041-1345(00)01515-3","article-title":"Discontinuation of immunosuppressive antimetabolite for parvovirus B19-associated anemia in kidney transplant patients.","volume":"32","author":"Shimmura","year":"2000","journal-title":"Transplant Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/ndt\/17.10.1840","article-title":"Eradication of parvovirus B19 infection after renal transplantation requires reduction of immunosuppression and high-dose immunoglobulin therapy.","volume":"17","author":"Liefeldt","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.24875\/RIC.19002921","article-title":"Treatment strategies and outcome of parvovirus b19 infection in kidney transplant recipients: a case series and literature review of 128 patients.","volume":"71","author":"Rosado-Canto","year":"2019","journal-title":"Rev Invest Clin."},{"key":"B16","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/cid\/cis1046","article-title":"Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: A retrospective study of 10 patients and review of the literature.","volume":"56","author":"Yoann","year":"2013","journal-title":"clinical infectious diseases"},{"key":"B17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.25259\/ijn_418_23","article-title":"Concomitant parvovirus B19 and CMV infection in a child with kidney transplant.","volume":"35","author":"Moghadam","year":"2025","journal-title":"Indian J Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1086\/504812","article-title":"Parvovirus B19 infection after transplantation: a review of 98 cases.","volume":"43","author":"Eid","year":"2006","journal-title":"Clin Infect Dis"},{"key":"B19","first-page":"785","article-title":"Parvovirus B19: A Rare Cause of Post-renal Transplant Anemia.","volume":"27","author":"Ahmed","year":"2017","journal-title":"J Coll Physicians Surg Pak"},{"key":"B20","unstructured":"Anemia and the outcomes in renal transplant recipients: a meta-analysis.\n          \n          5\n          \n            \n              Gang\n              H\n            \n            \n              Jun\n              L\n            \n            \n              Guodong\n              C\n            \n            \n              Lizhong\n              C\n            \n            \n              Jiang\n              Q\n            \n          \n          Oncotarget\n          \n          2015"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100681","DOI":"10.1016\/j.xkme.2023.100681","article-title":"Treatment options for anemia in kidney transplant patients: a review.","volume":"5","author":"Bonomini","year":"2023","journal-title":"Kidney Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000535071","article-title":"Roxadustat for patients with posttransplant anemia: a narrative review.","volume":"10","author":"Tang","year":"2023","journal-title":"Kidney Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1296702","DOI":"10.3389\/fphar.2023.1296702","article-title":"Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses.","volume":"14","author":"Ren","year":"2023","journal-title":"Front Pharmacol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1686727\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T06:34:42Z","timestamp":1765521282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1686727\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":24,"alternative-id":["10.3389\/fmed.2025.1686727"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1686727","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"article-number":"1686727"}}